Retinal fluid as the major biomarker in exudative macular disease is accurately visualized by
high-resolution three-dimensional optical coherence tomography (OCT), which is used …

Currently, the treatment for ocular neovascular diseases, including diabetic macular edema
(DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal …

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD (nAMD) that
accounts for a significant proportion of nAMD cases worldwide, and particularly in Asia …

Subretinal fibrosis is a major cause of the poor visual prognosis for patients with
neovascular age-related macular degeneration (nAMD). Myofibroblasts originated from …

Purpose Since non-adherence (NA) to intravitreal therapy with VEGF drugs is one of the
most important modifiable factors compromising treatment outcome of nAMD, the purpose of …

PURPOSE To report the incidence and risk factors for fibrosis at 10 years in a large cohort of
persons with neovascular age-related macular degeneration (nAMD). DESIGN …

Purpose To report the diagnosis and definitions, epidemiology, risk factors, and visual
outcomes of fibrosis in neovascular age-related macular degeneration (nAMD). Design …

Background Age-related macular degeneration (AMD), a leading cause of irreversible vision
impairment in the United States and globally, is a disease of the photoreceptor support …

Background To compare the change in lesion area over 4 years of follow-up in eyes with
neovascular age-related macular degeneration (nAMD) treated with anti-vascular …

Visual acuity is a key outcome measure in the treatment of neovascular age-related macular
degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations …